Bedrijfsoverzicht
Reviva Pharmaceuticals Holdings, Inc. is a biopharmaceutical entity dedicated to the discovery, development, and commercialization of next-generation therapeutics designed to address unmet medical needs within the central nervous system, respiratory, inflammatory, and cardiometabolic disease areas. The company operates within the Healthcare sector, specifically focusing on the Biotechnology industry, which implies a high-risk, high-reward environment driven by research and development cycles rather than established product sales. In terms of scale, the firm maintains a market capitalization of $9.88M and employs a workforce of 14 individuals, reflecting a very small-cap operational structure typical of early-stage or specialized biotech ventures. This limited market cap and the absence of reported annual revenue figures suggest that the company is currently in a phase where capital allocation is heavily weighted toward R&D activities rather than profit generation, positioning it as a speculative asset for investors seeking exposure to early clinical-stage innovations rather than cash-flow-positive pharmaceutical products.
Financiële gezondheid
The financial statements reveal a Net Income (TTM) of $-19,864,902, while Revenue (TTM) and EBITDA are not available, indicating that the company has not yet achieved commercial profitability or that revenues do not cover the substantial costs associated with its research and development operations. The significant gap between nominal revenue and substantial net losses highlights a cost structure dominated by overhead, clinical trial expenses, and research investments that have not yet been offset by product sales. The company reports a Free Cash Flow of $-17,137,860, which signifies a continuous outflow of capital required to sustain its operations and fund future development milestones, thereby limiting immediate financial flexibility without external financing. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a common characteristic for pre-revenue or pre-commercialization biotechnology firms where revenue recognition lags behind significant expenditure. Despite the negative earnings, the company holds $14.44M in cash against $406,875 in debt, resulting in a Debt to Equity ratio of 4.71, which indicates a highly leveraged balance sheet relative to its equity base. However, the Current Ratio stands at 2.08, suggesting that the company possesses sufficient liquid assets to cover its short-term liabilities without immediate distress. Furthermore, the Return on Equity is -420.0% and the Return on Assets is -80.3%, metrics that explicitly demonstrate that management has not yet generated value for shareholders or asset holders, as the returns are deeply negative due to accumulated losses.
Waarderingsbeoordeling
Valuation metrics for Reviva Pharmaceuticals Holdings, Inc. present a complex picture due to the lack of traditional profitability measures, with a Trailing P/E Ratio (TTM) listed as N/A and a Forward P/E of -0.93. The negative forward P/E implies that the market is pricing in expected future earnings that are currently negative, reflecting the high probability of continued losses in the near term. The Price to Book ratio is 0.52, indicating that the market values the company at less than half of its book value, which often occurs when the market perceives the assets as having limited immediate utility or when the cost of R&D exceeds the recorded book value. Alternative valuation metrics such as Price to Sales and EV/EBITDA are both N/A, suggesting that traditional multiple-based comparisons with established peers are not applicable for this specific asset at this stage of its lifecycle. Price action over the past year has been volatile, with a 52-Week High of $23.20 and a 52-Week Low of $0.59. Without a specific current price point provided in the source data to calculate the exact percentage, the stock's position relative to this range remains undefined, though the wide spread suggests significant price discovery and potential for substantial percentage-based movement. The Beta value is 0.64, which indicates that the stock's price volatility is lower than the broader market, a characteristic often seen in small-cap biotech firms that may be less sensitive to general market fluctuations but are highly sensitive to their own clinical trial outcomes.
Growth & Income
Regarding growth dynamics, the Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, reflecting the company's pre-revenue status where historical growth rates cannot be calculated. In the absence of positive earnings, the company does not generate a payout ratio, which is recorded as 0.0%, and consequently, it does not pay a Dividend Yield, as N/A. Because the company does not distribute dividends, any potential earnings generated in the future would theoretically be reinvested directly into research and development rather than paid out to shareholders. The overall growth and income profile of Reviva Pharmaceuticals Holdings, Inc. is characterized by a total reliance on capital infusion for expansion, with no current income stream to support shareholder returns or organic revenue expansion.